Lung CancerJoseph Aisner |
From inside the book
Results 1-3 of 28
Page 178
... cyclophosphamide , toxorubicin , methotrexate , and pro- carbazine ( CAMP ) . JAMA 240 : 2743 , 1978 38. Takita H , Marabella P , Edgerton F , Rizzo D : Cis - dichlorodiammine platinum ( II ) , adriamycin , cyclophosphamide , CCNU , and ...
... cyclophosphamide , toxorubicin , methotrexate , and pro- carbazine ( CAMP ) . JAMA 240 : 2743 , 1978 38. Takita H , Marabella P , Edgerton F , Rizzo D : Cis - dichlorodiammine platinum ( II ) , adriamycin , cyclophosphamide , CCNU , and ...
Page 179
... cyclophosphamide versus cyclo- phosphamide , methotrexate , 5 - FU , and hydroxyurea ( CMFH ) in the treatment of stage III non - small cell bronchogenic carcinoma : A randomized trial . Cancer Treat Rep 64 : 1131 , 1980 55. Miller TP ...
... cyclophosphamide versus cyclo- phosphamide , methotrexate , 5 - FU , and hydroxyurea ( CMFH ) in the treatment of stage III non - small cell bronchogenic carcinoma : A randomized trial . Cancer Treat Rep 64 : 1131 , 1980 55. Miller TP ...
Page 273
... cyclophosphamide ; Cc CCNU ; D = DTIC ; E etoposide ( VP16-213 ) ; F = fluorouracil ; H = hexamethylmelamine ; M methotresate ; Hy hydrosourea ; P procarbazine ; N nitrogen mustard ; Pr = prednisone ; Pt = platinum ; B = bleomycin ; V ...
... cyclophosphamide ; Cc CCNU ; D = DTIC ; E etoposide ( VP16-213 ) ; F = fluorouracil ; H = hexamethylmelamine ; M methotresate ; Hy hydrosourea ; P procarbazine ; N nitrogen mustard ; Pr = prednisone ; Pt = platinum ; B = bleomycin ; V ...
Contents
The Pathology of Lung Cancer | 1 |
Screening and Detection of Lung Cancer | 25 |
Prognostic Factors in Lung Cancer | 41 |
Copyright | |
11 other sections not shown
Common terms and phrases
adenocarcinoma antigens appear aspiration associated biopsy bone brain bronchogenic carcinoma Cancer Treat Rep cell type chemotherapy chest clinical combination combination chemotherapy compared complete considered currently demonstrated detection developed diagnosis difference disease dose early effect et al evaluation evidence extensive factors findings frequency given histologic hormone human immunotherapy important improved increased initial involvement irradiation lesions less levels limited liver lung cancer lymph nodes major median mediastinal mediastinum metastases methods months needle nodes normal observed Oncology patients percent performance status positive potential present primary prior procedures production prognostic factors pulmonary radiation therapy radiotherapy randomized received regimens reported resection response scans SCCL SCLC screening showed significant small cell carcinoma small-cell specific squamous staging suggested superior Surg surgery surgical survival symptoms Table techniques tests therapeutic therapy Thorac thoracotomy tissue treated treatment trials tumor vincristine York